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Experimental Methods  
Stimulated Raman Scattering (SRS) Microscopy A picoEmerald laser system 
(Applied Physics and Electronics) was used as the light source for SRS microscopy. It 
produces 2 ps pump (tunable from 770 nm – 990 nm, bandwidth 0.5 nm, spectral 
bandwidth ~ 7 cm-1) and Stokes (1031.2 nm, spectral bandwidth 10 cm-1) beams with 80 
MHz repetition rate. Stokes beam is modulated at 20 MHz by an internal electro-optic 
modulator. The spatially and temporally overlapped Pump and Stokes beams are 
introduced into an inverted laser-scanning microscope (FV3000, Olympus), and then 
focused onto the sample by a 25X water objective (XLPLN25XWMP, 1.05 N.A., 
Olympus). Transmitted Pump and Stokes beams are collected by a high N.A. 
condenser lens (oil immersion, 1.4 N.A., Olympus) and pass through a bandpass filter 
(893/209 BrightLine, 25mm, Semrock) to filter out Stokes beam. A large area (10×10 
mm) Si photodiode (S3590-09, Hamamatsu) is used to measure the pump beam 
intensity. A 64 V reverse-biased DC voltage is applied on the photodiode to increase the 
saturation threshold and reduce response time. The output current is terminated by a 
50Ω terminator and pre-filtered by a 19.2-23.6-MHz band-pass filter (BBP-21.4+, Mini-
Circuits) to reduce laser and scanning noise. The signal is then demodulated by a lock-
in amplifier (SR844, Stanford Research Systems) at the modulation frequency. The in-
phase X output is fed back to the Olympus IO interface box (FV30-ANALOG) of the 
microscope. 30 µs time constant is set for the lock-in amplifier. Correspondingly, 80 µs 
pixel dwell time is used, which gives a speed of 8.5 s/frame for a 320-by-320-pixel 
image. For 1664, 2035, 2167 and 2940 cm-1, the wavelengths of pump laser are 880.6, 
852.3, 842.8, and 791.3 nm, respectively. On-sample pump and modulated Stokes 
beam powers are 30 mW and 45 mW respectively for 1664 and 2940 cm-1; 30 mW and 
170 mW respectively for 2035, 2143, 2167 cm-1. Laser powers are monitored 
throughout image acquisition by an internal power meter and power fluctuations are 
controlled within 1%. 16-bit greyscale images are acquired by Olympus Fluoview 3000 
software. All data presented are from at least three independent experiments.  
Spontaneous Raman Spectroscopy Spontaneous Raman spectra were acquired 
using an upright confocal Raman spectrometer (Horiba Raman microscope; Xplora 
plus). A 532 nm YAG laser is used to illuminate the sample with a power of 12 mW on 
sample through a 100×, N.A. 0.9 objective (MPLAN N; Olympus). Data acquisition was 
performed with 80 s integration by the LabSpec6 software. For Glutamine solution, 
background was subtracted by measuring signal from non-solution region on the same 
sample. The spectra are normalized to 2147 cm-1. 
Same Raman cross-sections for C-D and C-H are confirmed by Spontaneous Raman 
measurements on pure DMSO and DMSO-d6. Same system throughput of pump lasers 
at two designated wavelengths for C-H and C-D SRS imaging are confirmed by SRS 
acquisitions on pure DMSO and DMSO-d6 at the C-H and C-D channels. 
Plasmid construction and molecular cloning. The plasmid pcDNA3.1-N-httQ97-GFP 
was a generous gift from Prof. Ron Kopito and Prof. F.-U. Hartl. L. Hartl. The mHtt-97Q 
was obtained by deleting the GFP sequence from the pcDNA3.1-N-httQ97-GFP plasmid. 
The mHtt-46Q and mHtt-46Q-GFP was obtained by deleting fragment from pcDNA3.1-
N-httQ97-GFP and mHtt-97Q. 97Q-Halo was obtained by exchanging GFP with Halotag 
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in pcDNA3.1-N-httQ97-GFP. The subcloning was done by GenScript USA Inc. For 
plasmid amplification, mHtt97Q-GFP and mHtt97Q were transformed into DH5α 
Escherichia coli cells. The cells were plated onto agar plates with respective antibiotics 
for selection for 14h. The resulting single colony was picked and grown in LB medium 
for 24 h. The cultures were collected, and the plasmids were purified by QIAGEN Maxi-
prep kit.  
Cell culture, transfection, metabolic labeling and imaging Deuterated glutamine 
DMEM was made by supplying glutamine-d5 (Cambridge Isotope) to glutamine deficient 
DMEM (Gibco). Deuterated leucine DMEM was made by supplying leucine-d10 
(Cambridge Isotope) and regular methionine (Sigma-Aldrich) to leucine and methionine 
deficient DMEM (Thermo Scientific). Deuterated glucose DMEM was made by supplying 
d7-glucose (Cambridge Isotope) to glucose deficient DMEM (Gibco). The solutions were 
sterile filtered by 0.22 µm low protein binding filter system (Corning). The filtered 
solutions were added with 10% FBS and 1% penicillin-streptomycin (Sigma-Aldrich) to 
make the complete media. Cultured HeLa-CCL2 (ATCC) cells were seeded onto 14 mm 
glass-bottom microwell dishes (MatTek Corporation) or coverslips (12mm, #1.5, Fisher) 
for 24 h prior to transfection. Cells were first grown in regular DMEM complete medium 
until they reached 70-90% confluence. The medium was switched to the designated 
deuterated medium immediately before transfection. Transfection of 1-µg plasmids 
encoding mHtt-97Q-GFP or mHtt97Q was performed using Lipofectamine 3000 
transfection reagent (Thermo Fisher). After 24h of protein expression, medium was 
switched to the pre-warmed DPBS buffer before imaging. Coverslips were collected and 
attached to a microscope slides (1mm thick, VWR) with imaging spacer (Sigma-Aldrich); 
and the glass-bottom dishes were covered with another coverslip (22x22 mm, #1.5, 
VWR) on the top. Confocal fluorescence images were obtained by the Olympus 
FluoView™ FV3000 confocal microscope with SRS setup described above. 
Induce and image stress granules HeLa cells. HeLa cells seeded on to glass-bottom 
microwell dishes were incubated with Gln-d5 DMEM for 24h after they reach 50% 
confluence. Before imaging, HeLa cells was treated with 0.1 mM NaAsO2 (Sigma 
Aldrich S7400) in regular DMEM for 1h at 37 ˚C, 5% CO2. Live-cell SRS imaging was 
performed by replacing the NaAsO2 containing medium with DPBS after 1h incubation.  
 
For labeling stress granules with Oligo (dT) probe, Cy3-(dT)30 oligonucleotide probe was 
purchased from IDT. After incubation with 0.1 mM NaAsO2 for 1h, cells were fixed in 4% 
formaldehyde in PBS for 25 min at room temperature and subsequently permeabilized 
with 0.1% Triton X-100 in 2x saline sodium citrate (SSC) for 15 min, then washed with 1 
M Tris, pH 8, for 5 min. Cells were blocked with 0.0005% BSA diluted in 2x SSC for 
20min, washed with 1 M Tris, pH 8, for 5 min, and incubated with hybridization buffer 
(1.3 ng oligo(dT) probe, 0.005% BSA, 10% dextran sulfate, and 25% formamide, diluted 
in 2x SSC) for 1 h in a humid chamber. Cells were subsequently washed twice with 4x 
SSC for 5 min and once with 2x SSC for 5 min. The cells were carried onto perform 
fluorescence imaging of Cy3 and SRS imaging in C-D and CH3 channels in DPBS 
buffer.  
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Cell culture and imaging of stable mouse embryonic stem (ES) cells continuously 
expressing mHtt-94Q-mEos2. Mouse D3 ES cells, which stably express mHtt-94Q-
mEOS2 (from Prof. Zhe Liu, HHMI), were maintained on 0.1% gelatin coated plates in 
the absence of feeder cells. The ES cell medium was prepared by supplementing 
knockout DMEM (Gibco, 10829018) with 15% FBS, 1 mM GlutaMAX (ThermoFisher, 
35050061), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM 2-
mercaptoethanol and 10 ng/ml of recombinant LIF (ThermoFisher, PMC9484). 24h 
before the imaging experiment, ES cells were seeded onto 14 mm glass-bottom 
microwell dishes (MatTek Corporation) pre-coated with Matrigel (Corning) in culture 
medium with 2 mM Gln-d5 in place of 1 mM GlutaMAX for 24 h. ES cell imaging 
experiments were performed in the ES cell imaging medium, which was prepared by 
supplementing FluoroBrite medium (Invitrogen) with 10% FBS, 1 mM glutamax, 0.1 mM 
nonessential amino acids, 1 mM sodium pyruvate, 10 mM Hepes (pH 7.2~7.5), 0.1 mM 
2-mercaptoethanol and 10 ng/ml of recombinant LIF.  
 
Treatment of Glutamine Synthetase Inhibitor in HeLa cells. Glutamine synthetase 
inhibitor L-Methionine sulfoximine (MSO) (CAS#15985-39-4) was purchased as solid 
from ACROS Organic. The white solid was dissolved in ddH2O to obtain 300 mM stock 
solution. Right before transfection, the stock solution was diluted 100 times with Gln-d5 
DMEM to reach final concentration of 3mM in DMEM1. The HeLa cells seeded onto 
coverslip or imaging dish were switched to MSO medium immediately before 
transfection and was incubated with the presence of MSO throughout the 24 h 
expression time. Before imaging, the MSO medium was changed to pre-warmed DPBS 
buffer. 
Hyperspectral SRS (hSRS) on Gln-d5 Labeled Aggregates. The experimental set-up 
we used for hSRS imaging was described above (Fig.1 and S1). In brief, two 
synchronized picosecond laser pulses (bandwidth 0.5nm) from the APE laser described 
above was used for hSRS imaging. One laser was fixed at the fundamental laser 
wavelength (1031.2 nm) and the other was tunable from 770 nm to 990 nm. We chose 
the center wavelength of the tunable laser to be at 791.8 nm, 842.8 nm and 880.8 nm 
for hsSRS imaging in the 2940 cm−1, the 2147 cm−1, and the 1660 cm-1 regions 
respectively. The step size of the tunable laser is 0.5 nm and an image is taken as the 
laser is tuned to each wavelength. 35 steps were collected to cover the full spectrum of 
2940 cm-1 and 2147 cm-1 regions, while 21 steps were used for 1660 cm-1 region. The 
collection of images was acquired as the hyperspectral SRS image and the spectra was 
acquired by defining specific area of interest on the images and plotting the SRS 
intensity at respectively wavenumber. The SRS intensities were background subtracted 
and normalized to laser power fluctuations. Spectral resolution is about 12 cm−1. A 25× 
water immersion objective (XLPLN25XWMP, 1.05 N.A., Olympus) was used to focus 
the lasers onto the sample, with typical optical power at the sample of 30 mW for the 
pump beam and 160 mW for the Stokes beam. Each SRS image has 320 × 320 pixels 
and takes 8 seconds to acquire. 
 
Treatment of Geldanamycin (GA) in HeLa cells. Geldanamycin (CAS# 30562-34-6) 
was purchased as solid from Cayman Chemical. The solid was first dissolved in DMSO 
(ATCC) to make a 50mM stock solution and further diluted with ddH2O to 100μM. The 
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aqueous GA solution was diluted by Gln-d5 DMEM or regular DMEM to reach the 
100nM GA concentrations. The HeLa cells seeded onto coverslip or imaging dish were 
switched to GA medium immediately before transfection and was incubated in the 
presence of GA throughout the 24h expression time. Further imaging experiments after 
24h were performed after changing the GA medium to pre-warmed DPBS buffer.  
 
FLIP (Fluorescence Loss In Photobleaching) on mHtt GA treated aggregates. FLIP 
experiments were performed by first defining regions of interest (ROI), which were 
always peripheral cytosolic part at least 5 μm away from the aggregate. An image was 
first collected at 5% of the bleaching power right before photobleaching takes place. 
The photobleaching was achieved by continuous illumination of ROI experiment with 40% 
of the 488nm laser from the Olympus Fluoview FV3000 microscope for 150s. After 
intense illumination, another image was acquired at the exact same position with same 
parameter as the image collected before photobleaching. The cytosolic regions and 
aggregates were analyzed separately. 
 
Image processing and data analysis Color-coding and intensity profile for all images 
were done by ImageJ. Spectral plotting and signal to background ratio calculations were 
performed in Graphpad Prism 8.1.1. Figures were assembled in Abode Illustrator.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S6 
 
Estimation of the SRS detection limit for Gln-d5 labeled mHtt-97Q ex1 proteins 
1) Signal-to-Noise ratio (S/N) limited: 
From our concentration curve (Fig. 1d), our detection limit for Gln-d5 solution c(Gln-d5) is 
3 mM when S/N=1. There is a total of 103 glutamine in the mHtt97Q exon1 sequence. 
The detection limit for mHtt-97Q protein c(mHtt)S/N is: 
 
𝑐(𝑚𝐻𝑡𝑡)𝑆/𝑁 =
𝑐(𝐺𝑙𝑛 − 𝑑5)
n(Q)
=
3 𝑚𝑀
103
= 29 𝜇𝑀 
 
2) Aggregation-signal to cellular-background ratio (SAgg/BCell) limited:  
The background signal originates from the labeling of glutamine residues in newly 
synthesized cytosolic proteins by Gln-d5. The average concentration of cytosolic 
proteins is 2 mM2,3 and the average length of proteins in eukaryotes is 438 amino acids4. 
Glutamine makes up 4.2 percent4 of the overall proteome and the cellular proteome 
synthesis rate is about 1% per hour5. In our case, we incubated the cell in Gln-d5 
medium for 24h for labeling. The detection limit is hence set by SAgg/BCell=1 when the 
concentration of Gln-d5 in mHtt proteins (n(Q)=103) is equal that in cytosolic proteins. 
The mHtt-97Q protein concentration (c(mHtt)Agg/Cell) is calculated by: 
 
𝑐(𝑚𝐻𝑡𝑡)𝑆𝐴𝑔𝑔/𝐵𝑐𝑒𝑙𝑙 =
𝑐(𝑐𝑦𝑡𝑜𝑠𝑜𝑙𝑖𝑐 𝐺𝑙𝑛−𝑑5)
𝑛(𝑄)
=
2𝑚𝑀∗438𝑎𝑎 𝑝𝑒𝑟 𝑝𝑟𝑜𝑡𝑒𝑖𝑛∗1%∗24ℎ∗4.2%
103 𝑄 𝑝𝑒𝑟 𝐻𝑡𝑡
=
8.83 𝑚𝑀 
103
= 86𝜇𝑀  
 
 
Compositional analysis of mHtt aggregates (Figs. 3d and 4a-b). 
With measured CH/CD ratios through Gln-d5 labeled aggregates, we can calculate the 
molar percentages of sequestered mHtt and non-mHtt proteins in the aggregates. Since 
we supply Gln-d5 in DMEM for metabolic incorporation, the Gln-d5 would unbiasedly 
label newly synthesized mHtt proteins and endogenous non mHtt proteins. The labeled 
(newly synthesized) non-mHtt proteins will contribute to C-D signals. We here discuss 
two extreme scenarios, in which the sequestered non-mHtt cytosolic proteins are either 
all newly synthesized proteins or pre-existing proteins.  
 
1) If the sequestered cytosolic non-mHtt proteins are all newly synthesized proteins:  
Because the newly synthesized cytosolic proteins are labeled by Gln-d5, they could 
contribute to the measured C-D channel SRS signals from the aggregates. First, on 
average, there are 6 C-H bonds on a side-chain of each amino acid. This is calculated 
by summing over the products of the number of side-chain C-H bonds from each amino 
acid and the relative abundance of this amino acid in human proteome4. Second, the 
average cytosolic proteins contain about 438 amino acids (aa)4. Third, Glutamine 
accounts for 4.2% in human proteome4. Fourth, the CH Raman cross-section is the 
same to CD6,7 (confirmed by DMSO-d6 and DMSO). Fifth, de novo glutamine synthesis 
is negligible in our experiments (see below Figs. S9 & S10),  
Assuming there are 𝑥 amount (molar percentage) of mHtt and (1- 𝑥) amount of other 
cytosolic non-mHtt proteins in the aggregates, we could have the following equation 
based on our measured CH/CD ratio: 
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𝐶𝐻
𝐶𝐷
=
438∗(1−𝑥)∗(1−4.2%)+49𝑥
103𝑥+438∗(1−𝑥)∗4.2%
∗
6
5
= 5.75                  (1) 
Here, CH signal comes from CH bonds of non-Gln aa of both non-mHtt proteins and 
mHtt proteins. CD signal comes from C-D bonds in both Gln-d5 labeled mHtt proteins 
and non-mHtt proteins. As stated above, average cytosolic proteins contain 438 aa, in 
which 4.2% percent are Gln and (1-4.2%) are non-Gln aa. In contrast, mHtt proteins 
have 103 Gln (Q) and 49 non-Gln aa. The normalized concentration of Non-Gln aa in 
the aggregates is hence: 438*(1-x)*(1-4.2%)+49*x. Similarly, the normalized 
concentration of Gln-d5 in the aggregates is: 103x+438*(1-x)*4.2%. Since non-Gln aa 
have an average of 6 side chain C-H and Gln-d5 has 5 labeled side chain C-D, a factor 
of 6/5 is multiplied above. From Eq.(1), the molar percentage of mHtt proteins in 
aggregates, x, was solved to be 42.7%, and the molar percentage of sequestered non 
mHtt proteins in aggregates is 57.3%. 
 
2) If the sequestered cytosolic non-mHtt proteins are all pre-existing proteins: 
The sequestered non-mHtt proteins are not labeled by Gln-d5 and contribute to no C-D 
signal. The C-D SRS signals only come from Gln-d5 labeling in the mHtt proteins. All 
Gln in sequestered non-mHtt proteins only contain C-H side chains. Hence, the CH/CD 
ratio should be: 
 
                                             
𝐶𝐻
𝐶𝐷
=
438∗(1−𝑥)+49𝑥
103𝑥
∗
6
5
= 5.75                                              (2) 
   
From Eq.2, the molar percentage of mHtt protein in aggregates, x, was solved to be 
49.6%, and the molar percentage of sequestered non-mHtt protein in aggregates is 
50.4%. 
 
Described above are two extreme conditions for sequestered cytosolic non-mHtt 
proteins. As the sequestered proteins should contain both pre-existing proteins and 
newly synthesized proteins, the real composition of the mHtt aggregation can be 
calculated from:  
                              
𝐶𝐻
𝐶𝐷
= [𝐴 ∗
438∗(1−𝑥)+49𝑥
103𝑥
+ 𝐵 ∗
438∗(1−𝑥)∗95.8%+49𝑥
103𝑥+438∗(1−𝑥)∗4.2%
] ∗
6
5
= 5.75              (3) 
where A+B=1. Hence, the two extreme conditions discussed above provide the lower 
and the upper limits of the molar percentage of mHtt proteins in aggregates, ranging 
from 42.7% to 49.6%. Respectively, the molar percentage of sequestered non-mHtt 
proteins ranges from 50.4% to 57.3%. On average, the molar percentage of mHtt 
proteins is 46% and that of non-mHtt proteins is 54%.  
 
Absolute concentrations of mHtt and non-mHtt proteins in the aggregates (Fig. 4 
c,d). 
To calculate absolute concentrations, we define two variables: 1) 𝑥  for the molar 
percentage of mHtt proteins in the aggregates, as defined above; and 2) 𝑦  for the 
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absolute concentration of total proteins in the aggregates. The absolute concentrations 
of mHtt and non-mHtt proteins are then x*y and (1-x)*y respectively. 
We take an aggregate, indicated as the green point in Fig. 4a and shown in Fig 4c, as 
one example for our calculation. We then selected three representative aggregates of 
different sizes from Fig. 4a and listed all calculated results in Table S1 below.  
Based on the C-D signals of aggregates and the concentration curve (Fig. 1d), 
generated under the same pump and Stokes powers, we measured the average C-D 
SRS intensity (SRS (C-D)) of the aggregate to be 478.1 a.u., which corresponds to a 
Gln-d5 concentrating of 212.2 mM. The CH/CD ratio for this aggregate is 11.5. Similarly, 
we calculated the upper and the lower concentration limit based on the two extreme 
conditions. 
 
1) If the sequestered cytosolic non-mHtt proteins are all newly synthesized proteins 
labeled by Gln-d5, then we have: 
 
                                          
𝐶𝐻
𝐶𝐷
=
438∗(1−𝑥)∗(1−4.2%)+49𝑥
103𝑥+438∗(1−𝑥)∗4.2%
∗
6
5
= 11.5    (4) 
   𝑥 ∗ 𝑦 ∗ 103 + (1 − 𝑥) ∗ 𝑦 ∗ 438 ∗ 4.2% = 212.2 𝑚𝑀   (5) 
Solving Eq. (4) and (5), we got x=20.6% and y=5.9 mM. As a result, the concentrations 
(and the molar percentages) of mHtt and non-mHtt proteins in this small aggregate are 
1.2mM (20.6%) and 4.7mM (79.4%) respectively. 
 
2) If the sequestered non-mHtt proteins are all pre-existing proteins without Gln-d5 
labeling, we have: 
         
𝐶𝐻
𝐶𝐷
=
438∗(1−𝑥)+49𝑥
103𝑥
∗
6
5
= 11.5    (6) 
  𝑦 ∗ 103𝑥 = 212.2 𝑚𝑀    (7) 
Solving Eq. (6) and (7), we got x=31.8% and y=6.5 mM. The concentrations (and the 
molar percentages) of mHtt and non-mHtt proteins in this small aggregate are 2.1mM 
(31.8%) and 4.4mM (68.2%) respectively. 
 
As we indicated above, these numbers set the upper and lower limits. The 
concentration of mHtt proteins in this small aggregate ranges from 1.2 mM to 2.1 mM 
and the concentration of non-mHtt proteins ranges from 4.4 to 4.7 mM.  
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The Small Agg  
Green dot in Fig. 4a 
If the sequestered 
non-mHtt proteins are 
all newly synthesized 
proteins 
If the sequestered 
non mHtt proteins 
are all pre-existing 
proteins 
Average 
Molar percentage of mHtt 20.6% 31.8% 25.7% 
Absolute mHtt conc. 1.2 mM 2.1 mM 1.7 mM 
Molar percentage of non-
mHtt proteins 
79.4% 68.2% 73.8% 
Sequestered non-mHtt 
protein conc. 
4.7 mM 4.4 mM 4.6 mM 
    
The medium Agg  
Red dot in Fig. 4a 
   
Molar percentage of mHtt 47.0% 53.2% 50.1% 
Absolute mHtt conc. 4.3 mM 5.1 mM 4.7 mM 
Molar percentage of non-
mHtt proteins 
53.0% 46.8% 50.0% 
Sequestered non-mHtt 
protein conc. 
4.8 mM 4.5 mM 4.7 mM 
    
The Large Agg  
Magenta dot in Fig. 4a 
 
  
Molar percentage of mHtt 56.9% 61.5% 59.2% 
Absolute mHtt conc. 5.6 mM 6.4 mM 6.0 mM 
Molar percentage of non-
mHtt proteins 
43.1% 38.5% 40.8% 
Sequestered non-mHtt 
protein conc. 
4.3mM 4.0 mM 4.2 mM 
 
Table S1. Quantification of mHtt-97Q and non-mHtt proteins in aggregates. 
Calculated results based on equations described above for a small aggregate (Fig. 4a, 
green point, 6.7 μm2 and Fig. 4c, SRS (C-D)=478.1 a.u., CH/CD=11.5); a medium 
aggregates (Fig. 4a, red point, 19.1 μm2 and Fig. 4d, SRS (C-D)=1190.3 a.u., 
CH/CD=5.1) and a large aggregates (Figure 4a, purple point, 36.5 μm2, SRS (C-
D)=1484.9 a.u, CH/CD=3.8).  
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Neurodegenerative 
Diseases 
Repetitive Amino Acid 
Sequence 
(number indicated) 
S/N 
limited 
Sensitivity 
S/B limited 
Sensitivity 
Huntington’s disease 
(HD) 
 mHtt-250Q  12 μM  35 μM  
 mHtt-150Q  19 μM  57 μM  
mHtt-97Q (Imaged in this work) 29 μM 86 μM 
mHtt-72Q 38 μM 113 μM 
mHtt-46Q (Imaged in this work) 57 μM 155 μM 
Spinocerebellar 
ataxia Type 1 (SCA1) 
Ataxin-1-92Q 22 μM 64 μM 
Spinocerebellar 
ataxia Type 3 (SCA3) 
Ataxin-3-84Q 27 μM 80 μM 
Spinocerebellar 
ataxia Type 7 (SCA7) 
Ataxin-7-92Q 24 μM 71 μM 
Spinocerebellar 
ataxia Type 17 (SCA17) 
Tata-Binding Protein (TBP)-79Q 30 μM 88 μM 
Amyotrophic Lateral 
Sclerosis (ALS) and 
Frontotemporal 
Dementia (FTD) 
Poly PR (PR)175 6 μM 134 μM 
Poly GA (GA)175 14 μM 168 μM 
Poly GR (GR)149 11 μM 155 μM 
Poly PA (PA)175 8 μM 157 μM 
Poly GP (GP)175 9.5 μM 141 μM 
 
Table S2. Calculated sensitivity limits for SRS imaging of representative repetitive 
amino-acid sequences by selective labeling of corresponding deuterated amino 
acids. Q: Glutamine, Gln; P: Proline, Pro; A: Alanine, Ala; G: Glycine, Gly; R: Arginine, 
Arg. Labeling by Gln-d5; Pro-d7; Ala-d4; Gly-d2; Arg-d7. 
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Figure S1. Energy diagram of stimulated Raman scattering (SRS). When the 
energy difference between the pump (green) and probe (blue) photons is resonant with 
the vibrational (Raman) transition of a C-D bond. The C-D bond would be excited to the 
vibrational excited state mediate by a virtual state (i.e. one grey ball, signifying C-D 
bond, on the left is excited to the upper level shown on the right).  For each vibrational 
excitation of C-D bond, a pump photon is consumed (Raman Loss) and a Stokes 
photon is created (Raman Gain). The SRS signal is then detected as either Raman 
Gain or Raman loss signal. In our experiments, we adjust the laser (pump=842.8 nm, 
stokes=1031.2 nm) to match the vibration frequency of Ωvib =2167 cm-1 for C-D bond on 
Gln-d5 and detect the Raman loss signal at the Pump wavelength. 
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Fig. S2. Detailed amino acid (aa) sequence information of mHtt-97Q-GFP and 
mHtt-97Q. The mHtt exon1 fragment (highlighted in big parentheses), comprises of N-
terminal 17 aa (red), polyQ (blue) and proline rich (purple) domain, is fused with GFP 
(green) by a linker region (black) followed by C-terminal myc and 6x His-tag (black).  
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Fig. S3 Time-lapse fluorescence tracking and quantification on aggregates 
formed by mHtt-97Q-GFP and Tetramethylrhodamine (TMR) labeled mHtt-97Q-
Halo proteins. a) Time-lapse fluorescence imaging of mHtt-97Q-GFP captures fast 
aggregation formation (i.e. at the 40 min) on the same set of cells. b) Quantification of 
GFP signals for newly formed small aggregates shows a 5-fold fluorescence increase 
compared to those in cytosol when the aggregates form (e.g. 40 min in a)). c) A 
representative fluorescence image for 5 μM TMR-ligand co-incubated mHtt-97Q-Halo 
proteins in cells with a newly formed small aggregate. Comparison of cytosolic TMR 
fluorescence with known-concentration TMR-ligand solutions suggests an average of 80 
μM cytosol polyQ concentration right after the aggregates form. This indicates that the 
average concentration of polyQ proteins reaches 400 μM in the newly formed small 
aggregates. Scale bars: 10 μm.  
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Fig. S4. Spectral change of Gln-d5 after metabolic incorporation into proteins in 
HeLa cells. The Raman spectrum of Gln-d5 after incorporated into cellular proteins 
(blue, peaked at 2167 cm-1) presents a change in spectral line-shape compared to that 
of 100 mM Gln-d5 solution (green, peaked at 2147 cm-1). The shifted major peak of 
2167 cm-1 (blue) matches with the Raman peak of Gln-d5 solids (red, 2167 cm-1). 
Overall, the Raman spectrum of Gln-d5 incorporated in cells (blue) shows combinatorial 
spectral features from both that of Gln-d5 solutions (green) and solids (red).  
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Fig. S5. Similar average Amide I intensities for mHtt-97Q-GFP and mHtt-97Q 
aggregates were observed. HeLa cells were grown in regular medium till optimal 
confluence and were transfected by (a) mHtt-97Q-GFP or (b) mHtt-97Q plasmids in 
Gln-d5 medium for 24h before imaging by SRS at Amide I frequency (1664 cm-1). (c) 
Quantification of average Amide I intensities for the two types of aggregates. mHtt-97Q-
GFP (1186±175.8, n=10), mHtt-97Q (1248±169.4, n=14). Scale bar: 10 μm. Error bar: 
SD. 
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Fig. S6. SRS imaging with Gln-d5 labeling doesn’t detect stress granules. Normal 
HeLa cells were pre-incubated in Gln-d5 medium for 24h and was then stressed in 0.1 
mM NaAsO2 for 1h. a) Cy3-Oligo (dT) was used to visualize and confirm the formations 
of stress granules in fixed HeLa cells (yellow, fluorescence). Representative stress 
granules are arrow-headed. These stress granules were not detected in either CH3 
(2940 cm-1, red) or C-D (2135 cm-1, cyan) SRS images. b) No obvious puncta-like stress 
granules are detected by live-cell SRS imaging at the C-D (2135 cm-1, cyan) and the 
CH3 (2940 cm-1, red) channels. Scale bars: 10 μm. 
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Fig. S7. SRS imaging and quantification of mHtt-46Q with and without GFP. a) 
Plasmid construct of mHtt-46Q-GFP. b) Fluorescence imaging (green) of mHtt-46Q-
GFP aggregates (white arrow-headed). SRS imaging of the same set of cells at CH3 
channel (2940 cm-1, red) and at the C-D channel (2167 cm-1, cyan). The C-D SRS 
images recapitulate the aggregates (white arrow-headed) of varying sizes and shapes 
shown in fluorescence. c) Plasmid construct of mHtt-46Q by deleting GFP. d) SRS 
imaging of mHtt-46Q aggregates at C-D channel (2167 cm-1, cyan, left), off-resonance 
channel (2035 cm-1, middle) and CH3 channel (2940 cm-1, red, right). e) Aggregate 
signal (SAgg) to cellular background (BCell) ratios (SAgg/BCell) of mHtt-46Q aggregates at 
C-D (6.33±1.9, n=12) and CH3 (1.45±0.24, n=12) channels and of mHtt-46Q-GFP 
aggregates at C-D (4.01±1.6, n=13) and CH3 (1.41±0.16, n=13) channels. (f) CH/CD 
ratios for 46Q (6.9±2.2, n=12) and 46Q-GFP (10.6±1.9, n=13) aggregates. Error bar: SD. 
Scale bars: 10 μm. 
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Fig. S8. SRS imaging of polyQ aggregates in stable embryonic stem cell-lines expressing 
mHtt-94Q-mEos2 proteins. Left, fluorescence imaging from mEos2 (green). Middle, SRS 
imaging at CH3 channel (2940 cm-1, red). Right, SRS imaging at C-D channel (2167 cm-1, cyan). 
Scale bar: 5 μm. 
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Note: Gln is a non-essential amino acid, which can be de novo synthesized by cells. 
However, the extensive demand makes it an essential supplement in culture medium. It 
is also reported to become a conditionally essential amino acid for cells under stress.8,9 
In both Figs. S9 and S10 below, we confirmed the Gln-d5 incorporation efficiency to be 
near 100%, meaning that Gln from de novo synthesis is close to 0%.  
 
 
Fig. S9. The labeling efficiency of Gln-d5 for mHtt-97Q aggregates approaches 
100%. (a-b) HeLa cells transfected by mHtt-97Q was incubated with (a) or without (b) 
3mM L-MSO, the Gln synthetase inhibitor1 for inhibiting de novo Gln synthesis in the 
Gln-d5 DMEM. (c) The L-MSO treated aggregates have similar intensity (984.1±160, 
n=9) with the non-treated ones (936.2±147, n=6). (d) Aggregates in HeLa cells, 
transfected by mHtt-97Q and incubated in normal DMEM (with 4mM Gln-d5) or DMEM 
with doubled Gln-d5 concentration (8mM), show no intensity difference (887.1±174, 
n=10 and 854.3±234, n=9 respectively). Our observations demonstrate that both 
inhibiting de novo Gln synthesis (c) and enhancing extracellular Gln concentrations (d) 
do not increase aggregate intensity. Our control experiments suggest that the labeling 
efficiency for the aggregates by Gln-d5 from medium is close to 100%. Scale bars: 10 
μm. Error bar: SD.  
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Fig. S10. D7-glucose incubation has no detectable signals in both mHtt-97Q-GFP 
and mHtt-97Q aggregations through de novo Gln synthesis. (a-b) HeLa cells were 
transfected by mHtt-97Q-GFP of in (a) d7-glucose medium for labeling de novo 
synthesized Gln and in (b) Gln-d5 medium for Gln incorporation for 24h. D7-glucose 
incubation shows almost no C-D signals (a, 2140 cm-1, CD on) while Gln-d5 incubation 
yields very bright aggregates in C-D channel (b, 2167 cm-1, CD on). GFP is used as a 
guidance for aggregates due to minimum C-D signals D7-glucose incubation (c) HeLa 
cells were first pre-incubated with d7-glucose DMEM for 24h to pre-label de novo 
synthesized Gln and were next transfected with mHtt-97Q plasmid in d7-glucose DMEM 
for another 24 h. No signals were detected for aggregates (c, 2140, CD on), suggesting 
a minimal level of Gln in aggregates comes from de novo synthesis. Scale bar: 10 μm. 
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Fig. S11. C-D spectral shift induced by mHtt aggregates is mainly caused by the 
narrowing of the shoulder peak. (a-b) To understand the C-D spectral difference 
between the cell background and protein aggregates, we performed spectral fittings on 
SRS spectra of cell background (blue dots in a) and protein aggregates (green dots in b) 
by three Lorentzian peaks (purple lines in a and b, sum shown as fitted blue and green 
lines in a and b) using Fityk 1.3.1. (c) Our fitting results illustrate that the observed dip 
around 2146 cm-1 in aggregates (Fig. 5c) is mainly caused by the narrowing (29.0 cm-1 
vs 36.5 cm-1) and the slight red-shift (2130 cm-1 vs 2134 cm-1) of the shoulder peak 1. (d) 
The relative intensity ratios of Peak1 to Peak2 remain the same for both aggregates and 
cell backgrounds. 
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Fig. S12. Geldanamycin (GA) inhibits or solubilizes aggregation formation from 
both mHtt-97Q-GFP and mHtt-97Q in live HeLa cells. It has been shown that GA 
inhibits HSP90; induces heat shock response, and inhibits/solubilized EGFP-Htt72Q 
aggregation in other cell lines in a dose-dependent manner10. We confirmed similar GA 
functions in HeLa cells for mHtt-97Q-GFP aggregations (a) and for mHtt-97Q 
aggregates (b). We counted the number of large aggregates in one dish (14 mm2) of 
HeLa cells transfected with same amount of mHtt-97Q plasmids but incubated with 
different GA concentration for 24h. Large aggregates were defined as aggregation area 
larger than 15 μm2. Scale bar: 10 μm. 
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Fig. S13. GA induces a spectral change for a subset of mHtt-97Q aggregates. (a-b) 
Upon 24 h 100 nM GA treatment, a subset of mHtt-97Q aggregates with smaller sizes 
and reduced intensity (a, arrow indicated) presents a decrease at the 2132 cm-1 
shoulder peak (indicated by grey dotted line) from the C-D SRS hyperspectra (b, mHtt-
97Q GA agg, n=5) compared to untreated mHtt-97Q aggregates (b, mHtt-97Q normal 
agg, n=20). (c) Similar hyperspectral dip at 2132 cm-1 was also observed for mHtt-97Q-
GFP aggregates (mHtt-97Q-GFP GA agg, n=7) compared to that of mHtt-97Q 
aggregates (mHtt-97Q GA agg) shown in (b). Scale bar: 10 μm. Error bar: SD. 
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Fig. S14. Fluorescence Loss In Photobleaching (FLIP) on GA treated mHtt-
97QGFP aggregates. mHtt-97Q-GFP was transfected into HeLa cells in Gln-d5 medium 
with 100 nM GA and incubated for 24h. a) A representative cell with a small aggregate 
surrounded by diffusive fluorescence was imaged by a 2% 488 nm laser. b) The same 
cell, imaged by the same 2% 488 nm laser, after its peripheral cytosolic fluorescence 
being photobleached by 40% 488 nm laser for 150 s. c) Ratiometric quantification of 
fluorescence signals after and before FLIP (Fafter/Fbefore) on the aggregates and the 
cytosolic proteins. After peripheral photobleaching, while the cytosolic fluorescent 
signals were significantly diminished (0.19±0.12, n=6), the fluorescent signals of 
aggregates remained unchanged (0.98±0.12, n=6). The FLIP result indicates that there 
is minimal protein exchange between the aggregates and the cytosolic diffusive mHtt 
proteins in the presence of GA. Scale bar: 10 μm. 
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Fig. S15. Fittings of the C-D SRS spectra suggest a hyper-hydrated hydrogen-
bonding environment for GA treated mHtt aggregates. To understand the dip 
induced by GA treatment (Fig. 6b), we performed spectral fitting for aggregates in 
solvents with descending hydrogen-bonding capacities and GA-treated aggregates. (a-d) 
The fitting was achieved by fitting the sum (colored lines) of three Lorentzian peaks 
(purple lines) to the experimental spectra (colored dots) using Fityk 1.3.1. (e-f) While the 
linewidths of both peak1 and peak2 had no obvious trend in different solvents (e), the 
peak1-to-peak2 ratios decreased monotonously with the increase of hydrogen-bonding 
abilities of the solvents (f, from DMSO to DPBS). GA-treated aggregation showed the 
lowest peak1 to peak2 ratio.  
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Fig. S16. CH/CD ratios show slight increase from small aggregates (GA Htt97Q, 
n=7) in cells with GA-induced heat-shock responses to those similar-sized 
aggregates (Htt97Q, n=12) in normal cells. Error bar: SEM.  
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